Alpha-1 15% + Liquid Alpha1-Proteinase Inhibitor (Human)
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alpha1-Antitrypsin Deficiency
Conditions
Alpha1-Antitrypsin Deficiency
Trial Timeline
Aug 13, 2021 → Aug 1, 2025
NCT ID
NCT04722887About Alpha-1 15% + Liquid Alpha1-Proteinase Inhibitor (Human)
Alpha-1 15% + Liquid Alpha1-Proteinase Inhibitor (Human) is a phase 1/2 stage product being developed by Grifols for Alpha1-Antitrypsin Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT04722887. Target conditions include Alpha1-Antitrypsin Deficiency.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04722887 | Phase 1/2 | Completed |
Competing Products
3 competing products in Alpha1-Antitrypsin Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VX-864 + Placebo | Vertex Pharmaceuticals | Phase 2 | 51 |
| Alpha-1 MP | Grifols | Phase 1/2 | 38 |
| Alpha-1 MP | Grifols | Phase 1/2 | 38 |